EA033171B1 - Полутвёрдая фармацевтическая композиция на водной основе, содержащая тапентадол - Google Patents

Полутвёрдая фармацевтическая композиция на водной основе, содержащая тапентадол

Info

Publication number
EA033171B1
EA033171B1 EA201600442A EA201600442A EA033171B1 EA 033171 B1 EA033171 B1 EA 033171B1 EA 201600442 A EA201600442 A EA 201600442A EA 201600442 A EA201600442 A EA 201600442A EA 033171 B1 EA033171 B1 EA 033171B1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical composition
composition containing
aqueous pharmaceutical
containing tapentadol
semisolid aqueous
Prior art date
Application number
EA201600442A
Other languages
English (en)
Other versions
EA201600442A1 (ru
Inventor
Ульрих Райнхольд
Марк Шиллер
Эва Вульстен
Сабине-Карине-Катрин Ингхельбрехт
Роже-Каролус-Аугуста Эмбрехтс
Ульрих Файль
Original Assignee
Грюненталь Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Грюненталь Гмбх filed Critical Грюненталь Гмбх
Publication of EA201600442A1 publication Critical patent/EA201600442A1/ru
Publication of EA033171B1 publication Critical patent/EA033171B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретение относится к мягкой фармацевтической композиции на водной основе, содержащей тапентадол или его физиологически приемлемую соль.
EA201600442A 2011-03-04 2012-03-02 Полутвёрдая фармацевтическая композиция на водной основе, содержащая тапентадол EA033171B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161449329P 2011-03-04 2011-03-04
EP11003603 2011-05-03

Publications (2)

Publication Number Publication Date
EA201600442A1 EA201600442A1 (ru) 2017-02-28
EA033171B1 true EA033171B1 (ru) 2019-09-30

Family

ID=44652117

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201600442A EA033171B1 (ru) 2011-03-04 2012-03-02 Полутвёрдая фармацевтическая композиция на водной основе, содержащая тапентадол
EA201300988A EA025194B1 (ru) 2011-03-04 2012-03-02 Полутвёрдая фармацевтическая композиция на водной основе, содержащая тапентадол

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201300988A EA025194B1 (ru) 2011-03-04 2012-03-02 Полутвёрдая фармацевтическая композиция на водной основе, содержащая тапентадол

Country Status (24)

Country Link
US (3) US9446008B2 (ru)
EP (3) EP2680834B1 (ru)
JP (3) JP6027549B2 (ru)
KR (2) KR102039320B1 (ru)
CN (1) CN103501774A (ru)
AU (2) AU2012224954C1 (ru)
BR (1) BR112013022556A8 (ru)
CA (1) CA2828637C (ru)
CY (1) CY1119725T1 (ru)
DK (1) DK2680834T3 (ru)
EA (2) EA033171B1 (ru)
ES (2) ES2910085T3 (ru)
HR (1) HRP20171836T1 (ru)
HU (1) HUE037491T2 (ru)
IL (2) IL227826B (ru)
LT (1) LT2680834T (ru)
MX (1) MX344473B (ru)
NO (1) NO2680834T3 (ru)
PL (1) PL2680834T3 (ru)
PT (2) PT3766489T (ru)
RS (1) RS56692B1 (ru)
SI (1) SI2680834T1 (ru)
WO (1) WO2012119729A1 (ru)
ZA (1) ZA201306480B (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE037491T2 (hu) 2011-03-04 2018-09-28 Gruenenthal Gmbh Félszilárd vizes, tapentadolt tartalmazó gyógyszerkészítmény
DK2680832T3 (da) 2011-03-04 2019-10-14 Gruenenthal Gmbh Vandig farmaceutisk formulering af tapentadol til oral administration
US8997860B2 (en) 2011-08-05 2015-04-07 Halliburton Energy Services, Inc. Methods for monitoring the formation and transport of a fracturing fluid using opticoanalytical devices
US9395306B2 (en) 2011-08-05 2016-07-19 Halliburton Energy Services, Inc. Methods for monitoring fluids within or produced from a subterranean formation during acidizing operations using opticoanalytical devices
US20140076550A1 (en) 2012-09-14 2014-03-20 Halliburton Energy Services, Inc. Systems and Methods for Detecting Microannulus Formation and Remediation
US9228940B2 (en) 2012-09-14 2016-01-05 Halliburton Energy Services, Inc. Systems, methods, and apparatuses for in situ monitoring of cement fluid compositions and setting processes thereof
US8619256B1 (en) 2012-09-14 2013-12-31 Halliburton Energy Services, Inc. Systems and methods for monitoring the properties of a fluid cement composition in a flow path
US20160136112A1 (en) * 2013-08-02 2016-05-19 Ratiopharm Gmbh Composition comprising tapentadol in a dissolved form
EP2845625A1 (en) 2013-09-04 2015-03-11 Grünenthal GmbH Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
EP3273953B1 (en) * 2015-03-27 2019-01-02 Grünenthal GmbH Stable formulation for parenteral administration of tapentadol
MX2019003257A (es) * 2016-09-23 2019-06-10 Gruenenthal Gmbh Formulacion estable para la administracion parenteral de tapentadol.
EP3826631A1 (en) * 2018-07-24 2021-06-02 Dr. August Wolff GmbH & Co. KG Arzneimittel Topical emulsion of an anticholinergic compound

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002067651A2 (de) * 2001-02-28 2002-09-06 Grünenthal GmbH Pharmazeutisch salze
WO2007128412A1 (en) * 2006-04-28 2007-11-15 Grünenthal GmbH Pharmaceutical combination comprising 3- (3-dimethylamin0-1-ethyl-2-methyl-pr0pyl) -phenol and an nsaid
WO2008110323A1 (de) * 2007-03-12 2008-09-18 Grünenthal GmbH Verwendung von 1-phenyl-3-dimethylamino-propanverbindungen zur therapie des neuropathieschmerzes
US20100272815A1 (en) * 2009-04-28 2010-10-28 Actavis Group Ptc Ehf Amorphous form of tapentadol hydrochloride

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775678A (en) * 1984-10-01 1988-10-04 Schering Corporation Clotrimazole cream
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
US6183758B1 (en) * 1998-01-29 2001-02-06 Highland Laboratories, Inc. Phytochemicals, nutrients & medication absorption &/or treatment
US6399087B1 (en) 2000-12-20 2002-06-04 Amphastar Pharmaceuticals, Inc. Propofol formulation with enhanced microbial inhibition
US20050176790A1 (en) * 2001-02-28 2005-08-11 Johannes Bartholomaus Pharmaceutical salts
PE20030527A1 (es) 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
WO2003077897A1 (en) 2002-03-15 2003-09-25 Cypress Bioscience, Inc. Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes
US20030191187A1 (en) 2002-04-01 2003-10-09 Lee Fang Yu Injectable pharmaceutical composition containing a non-steroidal anti-inflammatory drug and method for preparing the same
MXPA05002728A (es) 2002-09-13 2005-07-25 Cydex Inc Capsulas que contienen composiciones de relleno acuoso estabilizadas con ciclodextrina derivada.
US20040180915A1 (en) 2003-03-14 2004-09-16 Xanodyne Pharmacal, Inc. Methadone-containing compositions for parenteral administration and method of use thereof
JP2007538091A (ja) 2004-05-17 2007-12-27 ファーマコフォア・インコーポレイテッド 痛みを処置または予防するための組成物および方法
PL1612203T3 (pl) 2004-06-28 2007-12-31 Gruenenthal Gmbh Krystaliczne postacie chlorowodorku (-)-(1R,2R)-3-(3-dimetyloamino-1-etylo-2-metylo-propylo)fenolu
KR101204657B1 (ko) 2004-07-01 2012-11-27 그뤼넨탈 게엠베하 (1r,2r)-3-(3-디메틸아미노-1-에틸-2-메틸-프로필)-페놀을 함유하는 남용 방지 경구 투여 제형
US20110098284A1 (en) 2005-04-28 2011-04-28 Najib Babul Methods and compositions for treating pain
TWI329334B (en) 2005-12-02 2010-08-21 Chung Shan Inst Of Science Manufacture method of electromagnetic interference layer for the plasma display panel
US20080039405A1 (en) * 2006-04-25 2008-02-14 Croda, Inc. Modification of percutaneous absorption of topically active materials
WO2007128413A1 (en) 2006-04-28 2007-11-15 Grünenthal GmbH Pharmaceutical combination comprising 3- ( 3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol and paracetamol
MX2009000911A (es) 2006-07-24 2009-02-04 Janssen Pharmaceutica Nv Preparacion de (2r,3r)-3-(3-metoxifenil)-n,n,2-trimetilpentanamina .
EP1985292A1 (en) 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
WO2009067703A2 (en) 2007-11-23 2009-05-28 Nectid, Inc. Tapentadol compositions
BRPI0906467C1 (pt) 2008-01-25 2021-05-25 Gruenenthal Gmbh forma de dosagem farmacêutica com formato exterior modificado resistente à ruptura e com liberação controlada
NZ592437A (en) * 2008-10-30 2013-03-28 Gruenenthal Chemie A dosage form comprising tapentadol and an opioid antagonist
US20100227921A1 (en) 2009-03-03 2010-09-09 Shire Llc Amino acid and peptide carbamate prodrugs of tapentadol and uses thereof
US20110190267A1 (en) * 2010-01-05 2011-08-04 Shire Pharmaceuticals, Inc. Prodrugs of opioids and uses thereof
CN102821791B (zh) * 2010-03-30 2015-06-17 磷肌酸有限公司 透皮递送贴剂
GB201006200D0 (en) * 2010-04-14 2010-06-02 Ayanda As Composition
US20120270848A1 (en) * 2010-10-22 2012-10-25 Galleon Pharmaceuticals, Inc. Novel Compositions and Therapeutic Methods Using Same
HUE037491T2 (hu) * 2011-03-04 2018-09-28 Gruenenthal Gmbh Félszilárd vizes, tapentadolt tartalmazó gyógyszerkészítmény

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002067651A2 (de) * 2001-02-28 2002-09-06 Grünenthal GmbH Pharmazeutisch salze
WO2007128412A1 (en) * 2006-04-28 2007-11-15 Grünenthal GmbH Pharmaceutical combination comprising 3- (3-dimethylamin0-1-ethyl-2-methyl-pr0pyl) -phenol and an nsaid
WO2008110323A1 (de) * 2007-03-12 2008-09-18 Grünenthal GmbH Verwendung von 1-phenyl-3-dimethylamino-propanverbindungen zur therapie des neuropathieschmerzes
US20100272815A1 (en) * 2009-04-28 2010-10-28 Actavis Group Ptc Ehf Amorphous form of tapentadol hydrochloride

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TZSCHENTKE T. M. ET AL.: "Tapentadol hydrochloride. Analgesic, Mu-opioid receptor agonist, noradrenaline reuptake inhibitor", DRUGS OF THE FUTURE, vol. 31, no. 12, December 2006 (2006-12), pages 1053-1061, XPO02660111, ISSN: 0377-8282 the whole document *

Also Published As

Publication number Publication date
US20180133174A1 (en) 2018-05-17
EA201300988A1 (ru) 2014-06-30
ES2654407T3 (es) 2018-02-13
IL258357A (en) 2018-05-31
RS56692B1 (sr) 2018-03-30
IL227826A0 (en) 2013-09-30
US20160346229A1 (en) 2016-12-01
US20120225950A1 (en) 2012-09-06
DK2680834T3 (en) 2017-12-04
NO2680834T3 (ru) 2018-03-17
AU2012224954A1 (en) 2013-09-19
AU2017200040B2 (en) 2018-09-06
CA2828637A1 (en) 2012-09-13
JP6259042B2 (ja) 2018-01-10
JP6670283B2 (ja) 2020-03-18
US9446008B2 (en) 2016-09-20
EP2680834A1 (en) 2014-01-08
CA2828637C (en) 2019-06-11
SI2680834T1 (en) 2018-01-31
HUE037491T2 (hu) 2018-09-28
PT3766489T (pt) 2022-04-07
EP3290029B1 (en) 2020-09-02
KR102039320B1 (ko) 2019-11-01
AU2012224954C1 (en) 2017-04-06
CN103501774A (zh) 2014-01-08
WO2012119729A1 (en) 2012-09-13
KR101911362B1 (ko) 2018-10-25
PL2680834T3 (pl) 2018-03-30
KR20140013020A (ko) 2014-02-04
MX344473B (es) 2016-12-16
JP2014506900A (ja) 2014-03-20
HRP20171836T1 (hr) 2017-12-29
MX2013010100A (es) 2013-10-01
LT2680834T (lt) 2018-01-10
EP3766489B1 (en) 2022-03-16
BR112013022556A2 (pt) 2016-12-06
CY1119725T1 (el) 2018-06-27
AU2012224954B2 (en) 2016-10-20
ES2910085T3 (es) 2022-05-11
JP2017039756A (ja) 2017-02-23
JP2018065839A (ja) 2018-04-26
IL227826B (en) 2018-04-30
EA201600442A1 (ru) 2017-02-28
KR20180116463A (ko) 2018-10-24
EP3290029A1 (en) 2018-03-07
EA025194B1 (ru) 2016-11-30
JP6027549B2 (ja) 2016-11-16
PT2680834T (pt) 2018-01-25
EP2680834B1 (en) 2017-10-18
BR112013022556A8 (pt) 2018-01-16
ZA201306480B (en) 2014-05-28
AU2017200040A1 (en) 2017-02-02
EP3766489A1 (en) 2021-01-20

Similar Documents

Publication Publication Date Title
EA033171B1 (ru) Полутвёрдая фармацевтическая композиция на водной основе, содержащая тапентадол
IN2014CN02616A (ru)
AP2013007227A0 (en) Pharmaceutical composition
UA111717C2 (uk) Склад для перорального введення і ліпофільні солі метилналтрексону
EP2702054A4 (en) NOVEL BISAMINOQUINOLINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS PREPARED THEREFROM, AND USE THEREOF
MX349224B (es) Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa.
AP2014007399A0 (en) Phenyl-3-AZA-bicycloÄ3.1.0Ühex-3-YL-methanones andthe use thereof as medicament
MX348831B (es) Administración parenteral de tapentadol.
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
JO3154B1 (ar) عوامل مضادة لـ trpv4
MX2013008500A (es) Disialillacto-n-tetraosa (dslnt) o variantes, isomeros, analogos y derivados de la misma para prevenir o inhibir la enfermedad del intestino.
MX2013002948A (es) Composiciones farmaceuticas y nutraceuticas de acido abscisico.
EA201490761A1 (ru) R(+)-n-формилпропаргиламиноиндан
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
HK1197176A1 (en) Topical ophthalmological pharmaceutical composition containing regorafenib
MX348786B (es) Agentes osmoticos de polisacarido esterificado.
PT2755635E (pt) Composições aquosas que compreendem arbecacina
EP2609933A4 (en) AQUEOUS COMPOSITION FOR ADMINISTRATION
EP2851075A4 (en) PREPARATION WITH 6,7-UNSATED 7-CARBAMOYLMORPHINANE DERIVATIVE
MX2014004210A (es) Derivados de 2-oxo-piperidinilo.
GB201420685D0 (en) Aqueous disinfectant composition
HK1250664A1 (zh) 含有他噴他多的半固體水性藥物組合物
MX2012014969A (es) Composiciones farmaceuticas estables de amlodipina con telmisartan.
UA111066C2 (uk) Композиція, яка містить шелак та/або його сіль і натрію крохмальгліколят
EP2627655A4 (en) THERAPEUTIC 5,6,5-TRICYCLIC ANALOGUES

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU